Weibin Zhou1, Yanyun Gu, Hong Li, Min Luo. 1. Department of Endocrinology, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine (SJU-SM, formerly Shanghai Second Medical University), 197, Ruijin 2nd Road, Shanghai 200025, China.
Abstract
OBJECTIVE: To assess the cutoff values at different time points for impaired glucose regulation (IGR) and diabetes, the glucose curve and isolated 1-h hyperglycemia were monitored during an oral glucose tolerance test (OGTT). METHODS: Two thousand eight hundred and eighty-six subjects (1300 men and 1586 women) were recruited to have an OGTT. Plasma was collected at 0, 30, 60, 120, and 180 min to analyze glucose and insulin. The diagnosis of impaired fasting glucose, impaired glucose tolerance, and diabetes was based on World Health Organization and American Diabetes Association's criteria. Those with fasting plasma glucose (FPG) < 5.6 and 2-h plasma glucose (PG) < 7.8, but 1-h PG > or = 7.8 and < 11.1 mmol/l were defined as 1h-High7.8, and those with FPG < 7.0 and 2-h PG < 11.1, but 1-h PG > or =11.1 mmol/l as 1h-High11.1. The cutoff values were calculated by receiver operating characteristic (ROC) curve. The correlation between beta-cell function and the area under the curve of glucose (AUCg) and the shape index was analyzed with linear regression. RESULTS: The cutoff values for IGR were 5.6, 9.7, 10.1, 7.8 and 6.1 mmol/l for blood glucose at 0, 30, 60, 120 and 180 min, 24 for AUCg and 1.3 mmol/l for the shape index. The cutoff values for diabetes were 6.8, 11.2, 13, 11.1 and 7 mmol/l for 0, 30, 60, 120 and 180 min, 30.9 for AUCg and 2 mmol/l for the shape index. Both AUCg and the shape index were inversely related to beta-cell function. The profiles of glucose and insulin in the subgroup with isolated 1-h hyperglycemia were very different from those seen in subjects with normal glucose tolerance or IGR. CONCLUSIONS: The present study provides new information on measures other than the fasting and 2-h PG to evaluate glucose metabolism in vivo and stimulates further research aimed at assessing the value of the OGTT 1-h PG concentration prospectively.
OBJECTIVE: To assess the cutoff values at different time points for impaired glucose regulation (IGR) and diabetes, the glucose curve and isolated 1-h hyperglycemia were monitored during an oral glucose tolerance test (OGTT). METHODS: Two thousand eight hundred and eighty-six subjects (1300 men and 1586 women) were recruited to have an OGTT. Plasma was collected at 0, 30, 60, 120, and 180 min to analyze glucose and insulin. The diagnosis of impaired fasting glucose, impaired glucose tolerance, and diabetes was based on World Health Organization and American Diabetes Association's criteria. Those with fasting plasma glucose (FPG) < 5.6 and 2-h plasma glucose (PG) < 7.8, but 1-h PG > or = 7.8 and < 11.1 mmol/l were defined as 1h-High7.8, and those with FPG < 7.0 and 2-h PG < 11.1, but 1-h PG > or =11.1 mmol/l as 1h-High11.1. The cutoff values were calculated by receiver operating characteristic (ROC) curve. The correlation between beta-cell function and the area under the curve of glucose (AUCg) and the shape index was analyzed with linear regression. RESULTS: The cutoff values for IGR were 5.6, 9.7, 10.1, 7.8 and 6.1 mmol/l for blood glucose at 0, 30, 60, 120 and 180 min, 24 for AUCg and 1.3 mmol/l for the shape index. The cutoff values for diabetes were 6.8, 11.2, 13, 11.1 and 7 mmol/l for 0, 30, 60, 120 and 180 min, 30.9 for AUCg and 2 mmol/l for the shape index. Both AUCg and the shape index were inversely related to beta-cell function. The profiles of glucose and insulin in the subgroup with isolated 1-h hyperglycemia were very different from those seen in subjects with normal glucose tolerance or IGR. CONCLUSIONS: The present study provides new information on measures other than the fasting and 2-h PG to evaluate glucose metabolism in vivo and stimulates further research aimed at assessing the value of the OGTT 1-h PG concentration prospectively.
Authors: Heba M Ismail; Ping Xu; Ingrid M Libman; Dorothy J Becker; Jennifer B Marks; Jay S Skyler; Jerry P Palmer; Jay M Sosenko Journal: Diabetologia Date: 2017-09-27 Impact factor: 10.122
Authors: Joe J Simon; Marion A Stopyra; Esther Mönning; Sebastian Sailer; Nora Lavandier; Lars P Kihm; Martin Bendszus; Hubert Preissl; Wolfgang Herzog; Hans-Christoph Friederich Journal: J Clin Invest Date: 2020-08-03 Impact factor: 14.808
Authors: Ram Jagannathan; Mary Beth Weber; Ranjit M Anjana; Harish Ranjani; Lisa R Staimez; Mohammed K Ali; Viswanathan Mohan; K M Venkat Narayan Journal: Diabetes Res Clin Pract Date: 2020-02-11 Impact factor: 5.602
Authors: Stephanie T Chung; Joon Ha; Anthony U Onuzuruike; Kannan Kasturi; Mirella Galvan-De La Cruz; Brianna A Bingham; Rafeal L Baker; Jean N Utumatwishima; Lilian S Mabundo; Madia Ricks; Arthur S Sherman; Anne E Sumner Journal: Clin Endocrinol (Oxf) Date: 2017-08-06 Impact factor: 3.478
Authors: G Chen; X Zou; J Yao; Q Jiang; Y Zhang; M Tu; S Yang; S Xu; W Lin; H Huang; J Liang; L Li; L Lin Journal: J Endocrinol Invest Date: 2010-10-08 Impact factor: 4.256
Authors: Caroline K Kramer; Chang Ye; Anthony J G Hanley; Philip W Connelly; Mathew Sermer; Bernard Zinman; Ravi Retnakaran Journal: Diabetologia Date: 2015-03-12 Impact factor: 10.122
Authors: O Birnbaum-Weitzman; R Goldberg; B E Hurwitz; M M Llabre; M D Gellman; M Gutt; J R McCalla; A J Mendez; N Schneiderman Journal: Diabet Med Date: 2013-12-18 Impact factor: 4.359
Authors: Vasudha Ahuja; Pasi Aronen; T A Pramodkumar; Helen Looker; Angela Chetrit; Aini H Bloigu; Auni Juutilainen; Cristina Bianchi; Lucia La Sala; Ranjit Mohan Anjana; Rajendra Pradeepa; Ulagamadesan Venkatesan; Sarvanan Jebarani; Viswanathan Baskar; Teresa Vanessa Fiorentino; Patrick Timpel; Ralph A DeFronzo; Antonio Ceriello; Stefano Del Prato; Muhammad Abdul-Ghani; Sirkka Keinänen-Kiukaanniemi; Rachel Dankner; Peter H Bennett; William C Knowler; Peter Schwarz; Giorgio Sesti; Rie Oka; Viswanathan Mohan; Leif Groop; Jaakko Tuomilehto; Samuli Ripatti; Michael Bergman; Tiinamaija Tuomi Journal: Diabetes Care Date: 2021-04 Impact factor: 19.112